insurance

April

Ozempic

Vinci

<h3 id="key-takeaways">Key Takeaways</h3>
<ul>
 <li>ISRG shares plummeted over 10% to $360.50 on Friday, marking the sharpest decline since April 2022</li>
 <li>Second quarter earnings per share reached $2.80, surpassing the $2.50 consensus; revenue totaled $2.89B versus $2.82B expected</li>
 <li>Da Vinci procedure volume in the United States expanded just 12%, falling short of the 13% analysts anticipated</li>
 <li>Company maintained full-year outlook, forecasting expansion near the middle of its 13.5%–15.5% range</li>
 <li>Johnson &amp; Johnson’s competing Ottova surgical robot seeks regulatory approval before year-end</li>
</ul>
Intuitive Surgical delivered better-than-expected results for the second quarter across both earnings and revenue metrics, yet shareholders were dealt a harsh blow. ISRG shares tumbled more than 10% to close at $360.50 on Friday — representing the company’s sharpest single-session decline since April 2022 and marking the lowest closing price since January 2024, according to Dow Jones Market Data.
<a href="https://knockoutstocks.com/stock/ISRG" rel="noopener noreferrer nofollow"> <img src="https://knockoutstocks.com/api/stocks/ISRG/embed" alt="ISRG Stock Card"> Intuitive Surgical, Inc., ISRG </a>
The financial performance itself looked robust. The company posted adjusted earnings per share of $2.80, handily beating the Street’s $2.50 expectation. Total revenue climbed to $2.89 billion, exceeding the anticipated $2.82 billion.
So what triggered the massive selloff? Wall Street fixated on a single concern: decelerating procedure momentum.
<div class="embed-x">
 <blockquote class="twitter-tweet">
 INTUITIVE SURGICAL <a href="https://x.com/search?q=%24ISRG&amp;src=ctag&amp;ref_src=twsrc%5Etfw" rel="noopener noreferrer nofollow">$ISRG</a> Q2’26 EARNINGS HIGHLIGHTS
 <img src="https://s.w.org/images/core/emoji/17.0.2/72x72/1f539.png" alt="🔹"> Revenue: $2.89B (Est. $2.82B) <img src="https://s.w.org/images/core/emoji/17.0.2/72x72/1f7e1.png" alt="🟡">; +19% YoY <img src="https://s.w.org/images/core/emoji/17.0.2/72x72/1f539.png" alt="🔹"> Adj. EPS: $2.80 (Est. $2.51) <img src="https://s.w.org/images/core/emoji/17.0.2/72x72/1f7e2.png" alt="🟢">; +28% YoY <img src="https://s.w.org/images/core/emoji/17.0.2/72x72/1f539.png" alt="🔹"> Adj. Operating Income: $1.22B; +28% YoY <img src="https://s.w.org/images/core/emoji/17.0.2/72x72/1f538.png" alt="🔸"> Q2 EPS included an $0.08 benefit from refunds of tariffs paid in prior periods.
 FY26… <a href="https://t.co/cXyMJzhbin" rel="noopener noreferrer nofollow">pic.twitter.com/cXyMJzhbin</a>
 — Wall St Engine (@wallstengine) <a href="https://x.com/wallstengine/status/2077848999114215792?ref_src=twsrc%5Etfw" rel="noopener noreferrer nofollow">July 16, 2026</a>
 </blockquote>
</div>
Domestic da Vinci procedure activity expanded 12% during the second quarter, falling beneath the 13% growth rate analysts had forecasted and representing a step down from the 14% expansion recorded in the first quarter. On a worldwide basis, da Vinci procedures increased 15% compared to the prior year.
Company executives attributed the slowdown to patients postponing elective operations due to escalating insurance premiums and others opting for weight-loss medications such as Ozempic instead of surgical intervention. Procedures deemed medically essential, management emphasized, remained resilient.
Even with the earnings beat, Intuitive maintained its existing annual guidance — anticipating global da Vinci procedure expansion around the center of its 13.5% to 15.5% projected range. The Street had been hoping for an upward revision after the company raised its outlook during the previous quarter.
The medical device maker did boost its 2026 adjusted gross profit margin forecast to 68%–69% of revenue, an increase from the earlier projection of 67.5%–68.5%.
<h3 id="what-rbc-is-saying">What RBC Is Saying</h3>
<a href="https://coincentral.com/costco-cost-stock-edges-higher-after-rbc-calls-it-one-of-the-best-stories-in-retail/" rel="noopener noreferrer nofollow">RBC Capital Markets</a> analyst Shagun Singh challenged the market’s negative response. She maintained an Outperform rating on ISRG with a $575 price objective — trimmed modestly from $600 — characterizing the second quarter performance as a “clean beat.”
Singh characterized the domestic procedure deceleration as “transient rather than a structural shift in end-market demand,” noting that postponed cases are anticipated to materialize. She highlighted that international demand accelerated to 20% year-over-year expansion, demonstrating strength throughout Europe, Asia, and additional markets.
<blockquote>
 “We remain buyers,” Singh stated.
</blockquote>
<h3 id="jj-enters-the-ring">J&amp;J Enters the Ring</h3>
The quarterly results arrived amid intensifying competitive dynamics. <a href="https://coincentral.com/johnson-johnson-jnj-stock-drops-2-after-beating-earnings-heres-why/" rel="noopener noreferrer nofollow">Johnson &amp; Johnson</a> is advancing plans to introduce its proprietary surgical robot, the Ottova, engineered for soft-tissue operations in the upper abdominal region.
J&amp;J aims to secure regulatory approval by the conclusion of 2026. This initiative represents a direct challenge to Intuitive’s commanding market dominance, though the company presently faces no authorized competitor operating at comparable scale.
HCA Healthcare signaled weaker surgical procedure demand and an uptick in uninsured patient volumes earlier this week, providing additional industry context. Pandemic-era Affordable Care Act subsidies have now lapsed, prompting greater numbers of Americans to abandon coverage — a challenge Intuitive’s leadership team recognized.
Intuitive’s revised gross margin outlook of 68%–69% for 2026 represents the most current projection released by the organization.
The post <a href="https://blockonomi.com/intuitive-surgical-isrg-stock-plunges-10-despite-earnings-beat-buy-the-dip/" rel="noopener noreferrer nofollow">Intuitive Surgical (ISRG) Stock Plunges 10% Despite Earnings Beat — Buy the Dip?</a> appeared first on <a href="https://blockonomi.com" rel="noopener noreferrer nofollow">Blockonomi</a>.

Intuitive Surgical (ISRG) Stock Plunges 10% Despite Earnings Beat — Buy the Dip?

Table of Contents

Blockonomi

Other articles published on Jul 17, 2026

Join our free newsletter for daily crypto updates!